Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
World game at war: why some European nations have threatened a World Cup boycott 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
AMES, Iowa, April 30, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston
- Bank of America Merrill Lynch Global Healthcare Conference 2018 on May 16 at 5:15 PM PT (8:15PM ET) in Las Vegas
A live webcast of both conference presentations will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
